Cancer treatment is a challenging and highly stressful time for patients – but it also brings dangers for their cardiovascular health. Since cancer patients have on average a 2-6 times higher cardiovascular disease mortality risk than the general population1, prompt, reliable identification of at-risk patients is crucial. And once treatment is underway, close monitoring could help cardiologists detect potential biomarkers that may indicate the early stages of cardiac toxicity.
The recently published European Society of Cardiology (ESC) Guidelines for Cardio-oncology (available here2) reflect these priorities for the prevention and monitoring of cardiotoxicity risks. And with our comprehensive workflow solutions and advanced cardiovascular ultrasound systems, we’re ready to support you and your patients every step of the way along their cancer treatment journey.
Worldwide, an estimated
28.4 million new cancer cases are projected to occur in 2040,
a 47% rise from 2020 – making cardiology care for cancer survivors increasingly important3
Sometimes, our patients must move quickly between the cardio-oncology unit, echo lab and outpatient clinic – so we need to be very fast. We need to access reports very quickly – maybe even within an hour – so that’s why the cardio-oncology workflow needs to be perfect.”
Dr Jorge Solis, Hospital Universitario 12 Octubre, Madrid, Spain
To improve the integration of echocardiography in cardio-oncology, we need advanced echo tools that will work for large numbers of patients and be able to translate data into clear conclusions to help in clinical decision-making."
Dr Teresa López-Fernández, MD
La Paz University Hospital, IdiPAZ, CIBER CV, Madrid, Spain
Collaboration today is crucial because once you have made your diagnosis, you need to plan the treatment of the patient. Above all, you need to speak the same lan- guage – which is why it is so important to have a system in which you have all the data of your patients – from EKG, to echo, to cardiac CT.”
Dr Valentina Volpato, Nuovo Galeazzi Hospital, Milan, Italy
Solutions
Dynamic HeartModelA.I. and AutoStrain provide valuable insights to support cardiovascular monitoring and cardiotoxicity prevention, in close collaboration with oncologists and hematologists.”Dynamic HeartModelA.I. and AutoStrain provide valuable insights to support cardiovascular monitoring and cardiotoxicity prevention, in close collaboration with oncologists and hematologists.”
Dr Teresa López Fernández
Cardiac Imaging and Cardio-Oncology Unit Leader, La Paz University Hospital, Madrid, Spain
Documentation
External resources
1 www.escardio.org/The-ESC/Press-Office/Press-releases/Cancer-patients-are-at-higher-risk-of-dying-from-heart-disease-and-stroke
2 Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., Cutter, D. J., De Azambuja, E., De Boer, R. A., Dent, S. F., Farmakis, D., Gevaert, S. A., Gorog, D. A., Herrmann, J., Lenihan, D. (2022). 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal, 43(41), 4229–4361. https://doi.org/10.1093/eurheartj/ehac244.
3 Sung, H., Ferlay, J., Siegel, RL., Laversanne, M., Soerjomataram, I., Jemal, A., Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021: 71: 209- 249. https://doi.org/10.3322/caac.21660.
4 Philips Cardiovascular Workspace is the commercial name of the medical device Philips IntelliSpace Cardiovascular.
5 Advanced Visualization Workspace is the commercial name for IntelliSpace Portal.
You are about to visit a Philips global content page
Continue